Avinger, Inc.
10 articles with Avinger, Inc.
-
Avinger Expands Intellectual Property Portfolio
1/19/2021
Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today provided an update on the expansion of its intellectual property portfolio in 2020.
-
Avinger Initiates Full Commercial Launch of Tigereye(TM) Image-Guided CTO Crossing Catheter
1/15/2021
Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced full commercial launch of its Tigereye; image-guided chronic total occlusion (CTO) crossing system. With the initiation of full commercial launch, current and prospective accounts throughout the US and Germany
-
Avinger to Participate in HC Wainwright Conference
1/6/2021
Avinger, Inc., a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease, announced that its executive team will participate in the H.C. Wainwright Bioconnect 2021 Conference taking place virtually January 11-14, 2021.
-
Avinger Announces Annual Meeting Results
12/23/2020
Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced results of its annual meeting of stockholders (the "Annual Meeting"), concluded on December 23, 2020.
-
Avinger Adjourns Annual Meeting of Stockholders
12/11/2020
Scheduled to Reconvene December 23, 2020 Avinger Strongly Encourages Stockholders to Immediately Vote FOR Proposal 3
-
Avinger Expands Tigereye(TM) Limited Launch
12/4/2020
Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today provided an update on the limited launch of its Tigereye™ next generation image-guided chronic total occlusion (CTO) crossing system
-
Avinger Receives Nasdaq Extension, Recommends Stockholders Vote FOR All Proxy Proposals
12/1/2020
Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the company has received an extension until May 19, 2021 to regain compliance with the Nasdaq minimum bid price requirement for continued listing.
-
Avinger Reports Third Quarter 2020 Financial Results
11/10/2020
Avinger, Inc. today reported results for the third quarter ended September 30, 2020.
-
Avinger Announces Commercial Launch in Israel
11/5/2020
Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the commercial launch of its Lumivascular products and completion of its first patient cases in Israel.
-
Avinger to Announce Third Quarter 2020 Results on November 10, 2020
10/28/2020
Avinger, Inc., a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease, announced that it will release its financial results for the third quarter 2020 after the close of trading on Tuesday, November 10, 2020.